Acutus Medical Inc (OQ:AFIB)

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
 
See Regulatory Filings on SEC
Company Contact
Address: 2210 Faraday Ave Ste 100
CARLSBAD CA 92008-7225
Tel: N/A
Website: https://www.acutusmedical.com/us
IR: See website
<
Key People
Takeo Mukai
Chief Executive Officer, Chief Financial Officer, Senior Vice President 		   
Business Overview
Acutus Medical, Inc. is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. (Medtronic). The Company is solely focused on supporting the manufacturing and distribution of products to Medtronic. It manufactures transseptal crossing devices and associated accessories, such as integrated transseptal dilators and needles, fixed-curve or steerable introducers, and steerable sheaths (Products). These Products are used to access the left side, or left atrium, of the cardiac anatomy and are used in a range of medical applications, including in electrophysiology and structural heart procedures. The technology supports physicians during a critical component of an ablation or structural heart procedure. The transseptal crossing devices that it manufactures for Medtronic include versions that are length-, diameter- and tip-matched and designed to lock into the hub of sheaths used in many left-heart procedures.
Financial Overview
For the nine months ended 30 September 2023, Acutus Medical Inc revenues increased 29% to $14.7M. Net loss decreased 12% to $47.9M. Revenues reflect Disposables segment increase of 21% to $11.4M, Systems segment increase of 49% to $2M, United States segment increase of 46% to $8.7M, Europe segment increase of 10% to $6M. Lower net loss reflects Goodwill impairment decrease from $12M (expense) to $0K, Selling.
Employees: 225 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $1.27M as of Dec 31, 2023
Annual revenue (TTM): $19.66M as of Dec 31, 2023
EBITDA (TTM): -$66.74M as of Dec 31, 2023
Net annual income (TTM): -$32.79M as of Dec 31, 2023
Free cash flow (TTM): -$60.99M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 29,715,962 as of Mar 25, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More